RIDGEFIELD, Conn., Nov. 10, 2017 — Boehringer Ingelheim today announced that important sub-analyses from three major trials in anticoagulation care will be presented at the American Heart Association (AHA) Scientific Sessions 2017 in Anaheim, California, November 11-15. In total, five abstracts investigating Pradaxa® (dabigatran etexilate mesylate) and its reversal agent, idarucizumab, marketed in the U.S. as Praxbind®, have been accepted.
“We look forward to sharing important new insights about Pradaxa and idarucizumab from RE-DUAL PCI™, RE-CIRCUIT™ and RE-VERSE AD™, three pivotal trials that have all been published in the New England Journal of Medicine this year,” said Sabine Luik, M.D., senior vice president, Medicine & Regulatory Affairs, Boehringer Ingelheim Pharmaceuticals, Inc. “The safety and efficacy of Pradaxa has already been well-established, and these sub-analyses add to the growing body of evidence on its clinical impact in patients with atrial fibrillation.”
Details of the data presented at the AHA Scientific Sessions 2017 are as follows:
(Venue: Anaheim Convention Centre, Anaheim,
Subgroup analysis from the RE-DUAL
PCI trial: Dual antithrombotic therapy with
dabigatran in patients with atrial fibrillation
undergoing percutaneous coronary
Session Title: New Insights into the Risks, Benefits, and
Costs of Antithrombotic Therapy
Session Date: Tuesday, November 14, 10:45 a.m. – 12:00 p.m.
Presentation Time: 11:00 a.m. – 11:10 a.m.
Location: Main Event I (Hall D, Main Building)
Speaker: Jonas Oldgren
Idarucizumab in dabigatran-treated patients
requiring emergency surgery or intervention:
Updated/final results from the RE-VERSE AD
Session Title: Cardiovascular Surgery Research: The Cutting Edge
Presentation Date: Monday, November 13, 5:30 p.m. – 5:40 p.m.
Speaker: Jerrold Levy
Regional differences in patient characteristics
and outcomes during uninterrupted
anticoagulation with dabigatran versus
warfarin in catheter ablation of atrial
fibrillation: The RE-CIRCUIT study
Session Title: Stroke Risk Stratification and Prevention in Atrial Fibrillation
Session Date: Tuesday November 14, 10:30 a.m. – 11:45 a.m.
Location: Science and Technology Hall – Clinical Science Section
Speaker: Stefan H. Hohnloser
Idarucizumab is effective and safe in the
inhibition of dabigatran anticoagulation
in patients presenting with a gastrointestinal
bleeding: Insights from the RE-VERSE AD
Session Title: Clinical Studies and Trials for Prevention
Session Date: Monday, November 13, 3:00 p.m. – 4:15 p.m.
Location: Clinical Science III Section, Science and Technology Hall
Speaker: Menno V. Huisman
Monitoring of safety and effectiveness of
dabigatran relative to warfarin in routine care
Session Title: EP.RFO.21 – Pharmacoepidemiology
Session Date: Monday, November 13, 1:30 p.m. – 2:40 p.m.
Presentation Time: 2:30 p.m. – 2:45 p.m.
Location: Science and Technology Hall – Population Science Forum
Speaker: Chandrasekar Gopalakrishnan
More information on the Boehringer Ingelheim data due to be presented or published at the AHA Scientific Sessions 2017 can be found here.
Idarucizumab is the first and only approved specific reversal agent for a novel oral anticoagulant currently available. It is approved as a specific reversal agent for Pradaxa by the U.S. Food and Drug Administration (FDA) under accelerated approval. Continued approval for this indication may be contingent upon the results of an ongoing cohort case series study.
About Praxbind® (idarucizumab)
INDICATIONS AND USAGE
PRAXBIND is indicated in patients treated with Pradaxa® when reversal of the anticoagulant effects of dabigatran is needed:
- For emergency surgery/urgent procedures
- In life‐threatening or uncontrolled bleeding
This indication is approved under accelerated approval based on a reduction in unbound dabigatran and normalization of coagulation parameters in healthy volunteers. Continued approval for this indication may be contingent upon the results of an ongoing cohort case series study.
IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
- Dabigatran-treated patients have underlying diseases predisposing them to thromboembolic events. Reversing dabigatran therapy exposes patients to the thrombotic risk of their underlying disease. To reduce this risk, resumption of anticoagulant therapy should be considered as soon as medically appropriate.
Re-elevation of Coagulation Parameters
- Elevated coagulation parameters (e.g., activated partial thromboplastin time or ecarin clotting time) have been observed in a limited number of PRAXBIND-treated patients. If reappearance of clinically relevant bleeding together with elevated coagulation parameters is observed or if patients requiring a second emergency surgery/urgent procedure have elevated coagulation parameters, an additional full dose may be considered.
- There is insufficient clinical experience evaluating risk of hypersensitivity to idarucizumab, but a possible relationship could not be excluded. Risk of hypersensitivity (e.g., anaphylactoid reaction) to idarucizumab or excipients needs to be weighed cautiously against the potential benefit. If serious allergic reaction occurs, immediately discontinue PRAXBIND and institute appropriate treatment.
Risk in Patients with Hereditary Fructose Intolerance
- PRAXBIND contains 4 g sorbitol as an excipient. When prescribing PRAXBIND in patients with hereditary fructose intolerance consider the total daily amount of sorbitol/fructose consumption from all sources as serious adverse reactions (e.g. hypoglycemia, hypophosphatemia, metabolic acidosis, increase in uric acid, acute liver failure and death) may occur.
- The most frequently reported adverse reaction in ≥5% of idarucizumab-treated healthy volunteers was headache (12/224). The most frequently reported adverse reactions in ≥5% of patients were hypokalemia (9/123), delirium (9/123), constipation (8/123), pyrexia (7/123) and pneumonia (7/123).
- As with all proteins there is a potential for immunogenicity with idarucizumab. In treated patients, treatment-emergent antibodies with low titers were observed (9/224).
USE IN SPECIFIC POPULATIONS
Pregnancy and Nursing Mothers
- PRAXBIND should be given to a pregnant or nursing woman only if clearly needed.
Please see full Prescribing Information.
About Pradaxa® (dabigatran etexilate mesylate)
Indications and Usage
Pradaxa® (dabigatran etexilate mesylate) capsules is indicated:
- to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation
IMPORTANT SAFETY INFORMATION ABOUT PRADAXA
WARNING: (A) PREMATURE DISCONTINUATION OF PRADAXA INCREASES THE RISK OF THROMBOTIC EVENTS, (B) SPINAL/EPIDURAL HEMATOMA
(A) PREMATURE DISCONTINUATION OF PRADAXA INCREASES THE RISK OF THROMBOTIC EVENTS
Premature discontinuation of any oral anticoagulant, including Pradaxa, increases the risk of thrombotic events. If anticoagulation with Pradaxa is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant
(B) SPINAL/EPIDURAL HEMATOMA
Epidural or spinal hematomas may occur in patients treated with Pradaxa who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include:
- use of indwelling epidural catheters
- concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants
- a history of traumatic or repeated epidural or spinal punctures
- a history of spinal deformity or spinal surgery
- optimal timing between the administration of Pradaxa and neuraxial procedures is not known
Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary. Consider the benefits and risks before neuraxial intervention in patients who are or will be anticoagulated.
Pradaxa is contraindicated in patients with:
– active pathological bleeding;
– known serious hypersensitivity reaction (e.g., anaphylactic reaction or anaphylactic shock) to
– mechanical prosthetic heart valve
WARNINGS & PRECAUTIONS
Increased Risk of Thrombotic Events after Premature Discontinuation
Premature discontinuation of any oral anticoagulant, including Pradaxa, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events. If Pradaxa is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant and restart Pradaxa as soon as medically appropriate.
Risk of Bleeding
- Pradaxa increases the risk of bleeding and can cause significant and, sometimes, fatal bleeding. Promptly evaluate any signs or symptoms of blood loss (e.g., a drop in hemoglobin and/or hematocrit or hypotension). Discontinue Pradaxa in patients with active pathological bleeding.
- Risk factors for bleeding include concomitant use of medications that increase the risk of bleeding (e.g., anti-platelet agents, heparin, fibrinolytic therapy, and chronic use of NSAIDs). Pradaxa's anticoagulant activity and half-life are increased in patients with renal impairment.
- Reversal of Anticoagulant Effect: A specific reversal agent (idarucizumab) for dabigatran is available when reversal of the anticoagulant effect of dabigatran is needed:
- For emergency surgery/urgent procedures
- In life-threatening or uncontrolled bleeding
Hemodialysis can remove dabigatran; however clinical experience for hemodialysis as a treatment for bleeding is limited. Prothrombin complex concentrates or recombinant Factor VIIa may be considered but their use has not been evaluated. Protamine sulfate and vitamin K are not expected to affect dabigatran anticoagulant activity. Consider administration of platelet concentrates where thrombocytopenia is present or long-acting antiplatelet drugs have been used.
Thromboembolic and Bleeding Events in Patients with Prosthetic Heart Valves
The use of Pradaxa is contraindicated in patients with mechanical prosthetic valves due to a higher risk for thromboembolic events, especially in the post-operative period, and an excess of major bleeding for Pradaxa vs. warfarin. Use of Pradaxa for the prophylaxis of thromboembolic events in patients with AFib in the setting of other forms of valvular heart disease, including bioprosthetic heart valve, has not been studied and is not recommended.
Effect of P-gp Inducers & Inhibitors on Dabigatran Exposure
Concomitant use of Pradaxa with P-gp inducers (e.g., rifampin) reduces exposure to dabigatran and should generally be avoided. P-gp inhibition and impaired renal function are major independent factors in increased exposure to dabigatran. Concomitant use of P-gp inhibitors in patients with renal impairment is expected to increase exposure of dabigatran compared to either factor alone.
Reduction of Risk of Stroke/Systemic Embolism in NVAF
- For patients with moderate renal impairment (CrCl 30-50 mL/min), reduce the dose of Pradaxa to 75 mg twice daily when dronedarone or systemic ketoconazole is coadministered with Pradaxa.
- For patients with severe renal impairment (CrCl 15-30 mL/min), avoid concomitant use of Pradaxa and P-gp inhibitors.
The most serious adverse reactions reported with Pradaxa were related to bleeding.
- Most frequent adverse reactions leading to discontinuation of Pradaxa were bleeding & gastrointestinal (GI) events.
- Pradaxa 150 mg resulted in higher rates of major and any GI bleeds compared to warfarin.
- In patients ≥75 years of age, the risk of major bleeding may be greater with Pradaxa vs warfarin.
- Patients on Pradaxa 150 mg had an increased incidence of GI adverse reactions. These were commonly dyspepsia (including abdominal pain upper, abdominal pain, abdominal discomfort, and epigastric discomfort) and gastritis-like symptoms (including GERD, esophagitis, erosive gastritis, gastric hemorrhage, hemorrhagic gastritis, hemorrhagic erosive gastritis, and GI ulcer)
Other Measures Evaluated
In NVAF patients, a higher rate of clinical MI was reported in patients who received Pradaxa (0.7/100 patient-years for 150 mg dose) than in those who received warfarin (0.6).
About Boehringer Ingelheim
Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation.
Boehringer Ingelheim is one of the world's top 20 pharmaceutical companies. Headquartered in Ingelheim, Germany, the company operates globally with approximately 50,000 employees. Since its founding in 1885, the company has remained family-owned and today creates value through innovation for three business areas including human pharmaceuticals, animal health and biopharmaceutical contract manufacturing.
Boehringer Ingelheim is committed to improving lives and providing valuable services and support to patients and their families. Our employees create and engage in programs that strengthen our communities. Please visit our website to learn more about how we make more health for more people through our Corporate Social Responsibility initiatives.
In 2016, Boehringer Ingelheim achieved net sales of about $17.6 billion (15.9 billion euros). R&D expenditure corresponds to 19.6 percent of its net sales.
Boehringer Ingelheim Pharmaceuticals, Inc. either owns or uses the trademarks Pradaxa®, RE-VERSE AD™, RE-DUAL PCI™ and RE-CIRCUIT™ under license.
View original content:http://www.prnewswire.com/news-releases/boehringer-ingelheim-presents-new-data-for-pradaxa-and-its-specific-reversal-agent-idarucizumab-praxbind-at-aha-scientific-sessions-2017-300554063.html
SOURCE Boehringer Ingelheim
Latest posts by Brad Bennett (see all)
- Boost Your Business Growth in 2018 with MachPanel – Service Orchestration Platform (SOP) - February 22, 2018
- Matrix Is Recognized By New Jersey Alliance For Action - February 22, 2018
- Logos Evangelical Seminary Awarded $252,465 Campus Consortium Mobile Campus Grant - February 22, 2018